Clinical trialNCT05047523TerminatedPhase 3Interventional

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

SponsorAlexion Pharmaceuticals, Inc.Enrollment40Wilson Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson disease (WD).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Eugene S. Swenson, MD, PhD
Alexion Pharmaceuticals, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Research Site
Parkville, Australia
Research Site
South Brisbane, Australia

France

Research Site
Lille, France
Research Site
Toulouse, France

Germany

Research Site
Hanover, Germany
Research Site
Tübingen, Germany

Japan

Research Site
Kumamoto, Japan
Research Site
Kurume-shi, Japan
Research Site
Meguro-ku, Japan
Research Site
Sapporo, Japan

Poland

Research Site
Warsaw, Poland

South Korea

Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea

Spain

Research Site
Barcelona, Spain
Research Site
Esplugues de Llobregat, Spain
Research Site
Las Palmas de Gran Canaria, Spain
Research Site
Madrid, Spain
Research Site
Málaga, Spain
Research Site
Pamplona, Spain

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ALXN1840Standard of Care

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Sept 2021
Primary completion: 26 Jun 2023
Completion: 26 Jun 2023
Last update posted: 23 Oct 2024
Registered enrollment: 40
Registry id: NCT05047523

Cross-registrations

EU-CTR / CTIS (EudraCT)2021-001015-82

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.